Author:
Chen Pu,Wang Jianling,Yao Yao,Qu Yiping,Ji Meiju,Hou Peng
Funder
the Nature Science Basic Research Program of Shaanxi
Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. M. Pizzato, M. Li, J. Vignat, M. Laversanne, D. Singh et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 10, 264–272 (2022)
2. M. Celik, B.Y. Bulbul, S. Ayturk, Y. Durmus, H. Gurkan et al. The relation between BRAFV600E mutation and clinicopathological characteristics of papillary thyroid cancer. Med Glas (Zenica) 17, 30–34 (2020)
3. P. Fallahi, S.M. Ferrari, M.R. Galdiero, G. Varricchi, G. Elia et al. Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Semin Cancer Biol. 79, 180–196 (2022)
4. M. Molina-Vega, J. García-Alemán, A. Sebastián-Ochoa, I. Mancha-Doblas, J.M. Trigo-Pérez et al. Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice. Endocrine 59, 395–401 (2018)
5. V. Sukrithan, P. Jain, M.H. Shah, B. Konda, Kinase inhibitors in thyroid cancers. Endocr. Oncol. 3, e220062 (2023)